6 results about "Interleukin 18" patented technology

Provided are interleukin 18 (IL-18) variant polypeptides that comprise mutation(s) at one or more of G3, E6, D54, and N91, wherein amino acid positions are relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptide comprising (such as further comprising) at least one mutation at a residue selected from the group consisting of: C38, C68, C76, D98, S117, and C127, wherein the amino acid position is relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptides bind IL-18Rα and exhibit substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are IL-18 variant polypeptides that exhibit increased binding IL-18Rα relative to the wild-type IL-18 and substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are related nucleic acids, vectors, host cells, methods of producing IL-18 variant polypeptides, pharmaceutical compositions comprising IL-18 variant polypeptides, and uses of such pharmaceutical compositions.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present disclosure provides multispecific antigen binding proteins that bind to one or more cytokines, more particularly to pro-inflammatory cytokines. In particular, the present disclosure relates to multispecific antigen binding proteins that comprise an interleukin 18 (IL-18) binding domain and an interleukin 23 (IL-23) binding domain, and the use of said multispecific antigen binding proteins in medicine.

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.

Provided are methods, and reagents and kits for performing such methods, directed to treating subjects with cancer, including subjects with hematological cancers and subjects with solid tumors, including subjects with relapsed and / or refractory hematological cancers, subjects with metastatic, recurrent, relapsed, unresectable, and / or advanced tumors. Provided are methods of treating cancer comprising administering a decoy-resistant interleukin 18 (DR-18), including e.g., using combination therapies comprising administering a DR-18 and a multi-specific therapeutic. Methods may also include selecting a patient, and administering a DR-18 to result in enhanced cytotoxic activity of immune cells in the patient to treat the subject for cancer. Also provided are methods for administration of DR-18, to prime immune cells present in the subject, and administration of one or more agents that activate the primed immune cells, resulting in enhanced cytotoxic activity, thereby treating the cancer.

Described herein are methods of using fusion proteins consisting of elements such as one or more proteins / polypeptides capable of translocation into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. Proteins / polypeptides capable of translocation into the ER include, but are not limited to, immunoglobulins such as Fc regions, VHH antibodies and scFvs, and globular proteins such as serum albumin. IL-18 can be a precursor IL-18 similar to a native procytokine, wherein IL-18 is fused to the C-terminus of its propeptide or propeptide variant. These fusion proteins are useful in methods of treating cancer or fibrosis by activating IL-18 receptor complex (RC) signaling on a cell, releasing or exposing mature IL-18 in or adjacent to a tumor, and / or increasing memory CD8-T cell proliferation.